Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Ursodeoxycholic acid in the treatment of primary biliary cirrhosis

Abstract

Background/aims A double-blind, placebo-controlled trial of ursodeoxycholic acid (UDCA) was conducted in 180 patients with primary biliary cirrhosis (PBC) to define the efficacy and safety of UDCA. Efficacy was assessed by time to treatment failure defined as death; liver transplantation; histological progression; development of varices, ascites, or encephalopathy; doubling of total serum bilirubin levels; progression of fatigue or pruritus; drug toxicity; or voluntary withdrawal. Methods Patients with well-defined PBC underwent complete history, physical examination, liver chemistries, ultrasonography, upper endoscopy, and liver biopsy at entry as well as at 2 years. Liver chemistries were determined every 3 months. Results In patients receiving UDCA, treatment failure was delayed compared with the placebo-treated group (P = 0.0003, log rank test). Seven patients receiving UDCA died or required transplantation compared with 12 in the placebo group (P = 0.18). No patients discontinued UDCA because of side effects of toxicity. Conclusions UDCA was extraordinarily safe and well tolerated, and its use was associated with delayed progression of the disease as defined in this study. However, the lack of effects on symptoms, histology, and the need for liver transplantation or survival indicate that further evaluation is necessary to determine the ultimate role of UDCA in the treatment of PBC.

Overview

Integrity signals

Registry

Crossref · 10.1016/0016-5085(94)90021-3

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 23 references

Cited by

See all 508

Metadata

Authors
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., Lesage, G., Rossi, S. S., & Hofmann, A. F.
Affiliations
Mayo Clinic (US)
Venue
Gastroenterology
Publisher
Elsevier BV
Published
1994-05
Volume
106
Issue
5
Pages
1284-1290
ISSN
0016-5085 (ISSN-L)
OpenAlex
W1584416327
Cited by
487
References
23
Citations by year
2026: 5 · 2025: 13 · 2024: 6 · 2023: 4 · 2022: 10 · 2021: 5 · 2020: 9 · 2019: 17 · 2018: 15 · 2017: 19 · 2016: 11 · 2015: 8 · 2014: 12 · 2013: 4 · 2012: 8
FWCI
20.11
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Gastroenterology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
ursodeoxycholic acid, primary biliary cirrhosis, treatment efficacy, drug safety, disease progression, liver transplantation, mortality, serum bilirubin, pruritus, fatigue, bile acid therapy
MeSH terms
Adult, Bilirubin, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Liver, Liver Cirrhosis, Biliary, Male, Middle Aged, Ursodeoxycholic Acid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. https://app.cochat.ai/papers/10.1016/0016-5085(94)90021-3
The paper
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., Lesage, G., Rossi, S. S., & Hofmann, A. F. (1994). Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology. https://doi.org/10.1016/0016-5085(94)90021-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.